INTRASPINAL INFUSION OF NMDA ANTAGONISTS FOR THE TREATMENT OFINTRACTABLE NEUROPATHIC PAIN:  PRELIMINARY NEUROPATHOLOGY STUDIES



NIH Guide, Volume 22, Number 15, April 16, 1993



RFP AVAILABLE:  NIH-NIDR-2-93-3R



P.T. 34



Keywords:

  Pain 

  Treatment, Medical+ 



National Institute of Dental Research



The National Institute of Dental Research (NIDR) has a requirement for

the conduct of extensive studies in rats and, subsequently, in a larger

mammal, to identify the maximum safe intrathecal dose of three NMDA

antagonists, to compare the behavioral toxicity at doses giving equal

pain relief, and to make certain that chronic spinal administration of

the drugs does not damage the spinal cord.  The drugs to be

investigated are ketamine, dextrorphan, and memantine.  Request for

Proposals (RFP) No. NIH-NIDR-2-93-3R will be available on or about

April 26, 1993, with proposals due on or about June 7, 1993.



INQUIRIES



Requests for the RFP must be submitted in writing, to:



Marilyn R. Zuckerman

Contract Management Office

National Institute of Dental Research

Westwood Building, Room 533

Bethesda, MD  20892



.


Return to 1993 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.